Literature DB >> 33212380

ADAMTS13 activity, high VWF and FVIII levels in the pathogenesis of deep vein thrombosis.

Maria Teresa Pagliari1, Marco Boscarino1, Andrea Cairo1, Ilaria Mancini2, Ida Martinelli3, Paolo Bucciarelli3, Federica Rossi3, Frits R Rosendaal4, Flora Peyvandi5.   

Abstract

BACKGROUND: Deep vein thrombosis (DVT) is a common multi-factorial disease with a partially understood aetiology. Although the roles of high factor (F)VIII and von Willebrand factor (VWF) levels are recognized, that of ADAMTS13 is still unclear. AIM: To assess the association between ADAMTS13 activity levels, VWF antigen (VWF:Ag) and FVIII coagulant activity (FVIII:C) levels and DVT.
MATERIALS AND METHODS: 365 Italian DVT patients and 292 age- and sex-matched controls were considered. Plasma ADAMTS13 activity was measured using FRETS-VWF73 assay. VWF:Ag and FVIII:C were measured using immunoassay and one-stage clotting assay (ACL TOP analyzer), respectively. Quartile analyses were performed to evaluate the individual association between ADAMTS13 activity, VWF:Ag, FVIII:C and DVT. The combined effect of high VWF levels (> 4th quartile) and low ADAMTS13 levels (< 1st quartile) was evaluated using binary variables. All models were age- and sex-adjusted. Estimated risks were reported as Odds ratio (OR) with 95% confidence intervals (CI).
RESULTS: ADAMTS13 activity was lower in DVT patients (94% vs. 98% of controls). Patients with an ADAMTS13 activity <1st quartile (86%) showed a 1.6-fold increased risk of DVT (95%CI, 1.05-2.55). The combination of low ADAMTS13 activity and high VWF:Ag levels was associated with a 15-fold increased risk (95%CI, 7.80-33.80). VWF:Ag and FVIII:C were associated to DVT with a dose-response relationship.
CONCLUSIONS: ADAMTS13 activity < 86% was associated with a moderate risk of DVT. The co-presence of low ADAMTS13 activity and high VWF levels resulted in a strong synergistic effect on DVT risk. The association of VWF:Ag and FVIII:C with DVT was confirmed.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ADAMTS13 human protein; Deep vein thrombosis; Factor VIII; Risk factor; von Willebrand factor

Mesh:

Substances:

Year:  2020        PMID: 33212380     DOI: 10.1016/j.thromres.2020.10.037

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  5 in total

Review 1.  COVID-19 Sepsis: Pathogenesis and Endothelial Molecular Mechanisms Based on "Two-Path Unifying Theory" of Hemostasis and Endotheliopathy-Associated Vascular Microthrombotic Disease, and Proposed Therapeutic Approach with Antimicrothrombotic Therapy.

Authors:  Jae C Chang
Journal:  Vasc Health Risk Manag       Date:  2021-06-01

Review 2.  Pathogenesis of Two Faces of DVT: New Identity of Venous Thromboembolism as Combined Micro-Macrothrombosis via Unifying Mechanism Based on "Two-Path Unifying Theory" of Hemostasis and "Two-Activation Theory of the Endothelium".

Authors:  Jae C Chang
Journal:  Life (Basel)       Date:  2022-01-31

3.  Construction and validation of a novel coagulation-related 7-gene prognostic signature for gastric cancer.

Authors:  Bofang Wang; Dan Zou; Na Wang; Haotian Wang; Tao Zhang; Lei Gao; Chenhui Ma; Peng Zheng; Baohong Gu; Xuemei Li; Yunpeng Wang; Puyi He; Yanling Ma; Xueyan Wang; Hao Chen
Journal:  Front Genet       Date:  2022-08-29       Impact factor: 4.772

4.  Inflammatory biomarkers in pregnant women with COVID-19: a retrospective cohort study.

Authors:  Andrea Lombardi; Silvia Duiella; Letizia Li Piani; Agnese Comelli; Ferruccio Ceriotti; Massimo Oggioni; Antonio Muscatello; Alessandra Bandera; Andrea Gori; Enrico Ferrazzi
Journal:  Sci Rep       Date:  2021-06-25       Impact factor: 4.379

5.  The ADAMTS13-von Willebrand factor axis in COVID-19 patients.

Authors:  Ilaria Mancini; Luciano Baronciani; Andrea Artoni; Paola Colpani; Marina Biganzoli; Giovanna Cozzi; Cristina Novembrino; Massimo Boscolo Anzoletti; Valentina De Zan; Maria Teresa Pagliari; Roberta Gualtierotti; Stefano Aliberti; Mauro Panigada; Giacomo Grasselli; Francesco Blasi; Flora Peyvandi
Journal:  J Thromb Haemost       Date:  2020-12-18       Impact factor: 16.036

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.